CATAFLAM

Compare CATAFLAM  to:
Compare
Compare

Generic Name for CATAFLAM

Diclofenac potassium 50mg; tabs.

Legal Classification:

Rx

Pharmacological Class for CATAFLAM

NSAID (benzeneacetic acid deriv.).

Manufacturer of CATAFLAM

Novartis Pharmaceuticals Corp

Indications for CATAFLAM

Osteoarthritis. Rheumatoid arthritis. Ankylosing spondylitis.

Adult dose for CATAFLAM

Osteoarthritis: 50mg 2–3 times daily. Rheumatoid arthritis: 50mg 3–4 times daily. Ankylosing spondylitis: 25mg 4 times daily, may add 25mg at bedtime.

Children's dosing for CATAFLAM

Not recommended.

Contraindications for CATAFLAM

Aspirin allergy. Late pregnancy. Coronary artery bypass graft surgery.

Warnings/Precautions for CATAFLAM

Advanced renal disease: not recommended. Peptic ulcer. GI bleeding. Monitor AST/ALT within 4 weeks and then periodically; also blood, hepatic, and renal function in chronic use. Edema. Cardiac failure. Hypertension. Hepatic porphyria. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for CATAFLAM

Digoxin, methotrexate, cyclosporine, lithium toxicity. Antagonizes diuretics. May increase serum potassium level with K+-sparing diuretics. Avoid aspirin. Monitor oral anticoagulants, insulin and sulfonylureas. Increased risk of GI bleed with alcohol.

Adverse Reactions for CATAFLAM

Peptic ulcer, GI bleeding, elevated AST/ALT, abdominal discomfort, constipation, diarrhea, indigestion, nausea, abdominal distention, headache, dizziness, fluid retention, rash (discontinue if occurs), pruritus, tinnitus. See literature re: risk of cardiovascular events.

How is CATAFLAM supplied?

Tabs—100

Related Disease:

Ankylosing spondylitis
Arthritis~NSAIDs
Rheumatoid arthritis

Related Resources

Arava Boxed Warning updated to include severe liver injury

July 13, 2010

The FDA has updated the Boxed Warning of Arava (leflunomide, from sanofi aventis) to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced.

Phase 3 study of Lodotra for the treatment of rheumatoid arthritis (RA)

June 17, 2010

Horizon Pharma announced that data from its Phase 3 study of Lodotra showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

Phase 3 trial of Lodotra for rheumatoid arthritis

June 16, 2010

Horizon Pharma announced positive results from its Phase 3 registration study of Lodotra (prednisone tablet), that showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Salonpas Pain Relief Patch and Salonpas Arthritis Pain patch available

May 24, 2010

Hisamitsu announced the launch of Salonpas Pain Relief Patch (10% methyl salicylate and 3% I-menthol) and Salonpas Arthritis Pain patch (10% methyl salicylate and 3% I-menthol) for the temporary relief of mild to moderate aches and pains of the muscles and joints associated with arthritis, sprains, strains, bruises and simple backaches experienced by patients age ≥18 years.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions